News
5dOpinion
Zacks Investment Research on MSN5 Small Drug Stocks to Buy Amid Trump's New Tariff ThreatsThe uncertainty around tariffs and trade production measures has muted economic growth. President Trump has once again ...
Del-zota is designed for patients with mutations amenable to exon 44 skipping, which is just 7% of the overall DMD patient ...
Solid Biosciences' DMD gene therapy shows promise with SGT-003 and strong cash backing through 2027. Click here to read an ...
Taiho Pharmaceutical’s investigational Duchenne muscular dystrophy (DMD) therapy, pizuglanstat, has shown no benefit in a Phase III trial.
Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy ...
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AGAMREE and is publishing this notice of that determination as required by law. FDA has made the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results